Immunoadsorption in SLE: Three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity

Atherosclerosis Supplements

Volumn 10, Issue 5, 2009, Pages 114-121

  Biesenbach, P ^a   Schmaldienst, S ^a   Smolen, J S ^a   Horl W H ^a   Derfler, K ^a   Stummvoll, G H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

apheresis; Globaffin; Ig Therasorb; immunoadsorption; Immunosorba; SLE

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; AZATHIOPRINE; CHLOROQUINE; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C4; CREATININE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; GLUCOCORTICOID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN M; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STAPHYLOCOCCUS PROTEIN A; SYNTHETIC PEPTIDE;

ADULT; ALBUMIN BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT BLOOD LEVEL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ACTIVITY; DISEASE EXACERBATION; FEMALE; FOLLOW UP; GASTROINTESTINAL INFECTION; HUMAN; IMMUNOADSORPTION; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY BIOPSY; KNEE ARTHRITIS; LUPUS ERYTHEMATOSUS NEPHRITIS; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; URINALYSIS; URINE SEDIMENT;

ADULT; ANALYSIS OF VARIANCE; ANTIBODIES, ANTINUCLEAR; AUSTRIA; AUTOANTIBODIES; BINDING SITES, ANTIBODY; BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; EQUIPMENT DESIGN; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSORBENT TECHNIQUES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; PEPTIDES; PROTEINURIA; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL PROTEIN A; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 72649104780     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(09)71824-0     Document Type: Article

References (47)

1. Sultan S.M., Begum S., and Isenberg D.A. Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology (Oxford) 42 2 (2003) 230-234
2. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: Measures of overall disease activity. Arthritis Rheum 50 11 (2004) 3418-3426
3. Ebling F.M., and Hahn B.H. Pathogenic subsets of antibodies to DNA. Int Rev Immunol 5 1 (1989) 79-95
4. Houssiau F.A., D'Cruz D., Vianna J., and Hughes G.R. Lupus nephritis: the significance of serological tests at the time of biopsy. Clin Exp Rheumatol 9 4 (1991) 345-349
5. Maddison P.J., and Reichlin M. Deposition of antibodies to a soluble cytoplasmic antigen in the kidneys of patients with systemic lupus erythematosus. Arthritis Rheum 22 8 (1979) 858-863
6. Ohnishi K., Ebling F.M., Mitchell B., Singh R.R., Hahn B.H., and Tsao B.P. Comparison of pathogenic and non-pathogenic murine antibodies to DNA: antigen binding and structural characteristics. Int Immunol 6 6 (1994) 817-830
7. Raz E., Brezis M., Rosenmann E., and Eilat D. Anti-DNA antibodies bind directly to renal antigens and induce kidney dysfunction in the isolated perfused rat kidney. J Immunol 142 9 (1989) 3076-3082
8. Madaio M.P., Carlson J., Cataldo J., Ucci A., Migliorini P., and Pankewycz O. Murine monoclonal anti-DNA antibodies bind directly to glomerular antigens and form immune deposits. J Immunol 138 9 (1987) 2883-2889
9. Austin H.A., Klippel J.H., Balow J.E., le Riche N.G., Steinberg A.D., Plotz P.H., et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314 10 (1986) 614-619
10. Bansal V.K., and Beto J.A. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 29 2 (1997) 193-199
11. Steinberg A.D., and Steinberg S.C. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34 8 (1991) 945-950
12. Wallace D.J. Severe lupus. In: Hochberg M.C., Silman A.J., Smolen J.S., Weinblatt M.E., and Weisman M.H. (Eds). Rheumatology. 3 ed. (2003), Mosby, Edinburgh 1419-1425
13. Schroeder J.O., Euler H.H., and Loffler H. Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Ann Intern Med 107 3 (1987) 344-346
14. Lewis E.J. Plasmapheresis therapy is ineffective in SLE. Lupus Nephritis Collaborative Study Group. J Clin Apheresis 7 3 (1992) 153
15. Wallace D.J., Goldfinger D., Pepkowitz S.H., Fichman M., Metzger A.L., Schroeder J.O., et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apheresis 13 4 (1998) 163-166
16. Aringer M., Smolen J.S., and Graninger W.B. Severe infections in plasma- pheresis-treated systemic lupus erythematosus. Arthritis Rheum 41 3 (1998) 414-420
17. Blake J.S., and Butani L. TI - Rapidly progressive lupus glomerulonephritis and concomitant microangiopathy in an adolescent. Lupus 11 (2002) 533-535
18. Jones J.V., Cumming R.H., Bacon P.A., Evers J., Fraser I.D., Bothamley J., et al. Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus. Q J Med 48 192 (1979) 555-576
19. Wallace D.J. Apheresis for lupus erythematosus. Lupus 8 3 (1999) 174-180
20. Gaubitz M., Seidel M., Kummer S., Schotte H., Perniok A., Domschke W., et al. Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus. J Autoimmun 11 5 (1998) 495-501
21. Matic G., Bosch T., and Ramlow W. Background and indications for protein A-based extracorporeal immunoadsorption. Ther Apher 5 5 (2001) 394-403
22. Langone J.J. Immune complex formation enhances the binding of staphylococcal protein A to immunoglobulin G. Biochem Biophys Res Commun 94 2 (1980) 473-479
23. Ronspeck W., Brinckmann R., Egner R., Gebauer F., Winkler D., Jekow P., et al. Peptide based adsorbers for therapeutic immunoadsorption. Ther Apher Dial 7 1 (2003) 91-97
24. Koll R.A. Ig-Therasorb immunoadsorption for selective removal of human immunoglobulins in diseases associated with pathogenic antibodies of all classes and IgG subclasses, immune complexes, and fragments of immunoglobulins. Ther Apher 2 2 (1998) 147-152
25. Schneider K.M. Plasmapheresis and immunoadsorption: different techniques and their current role in medical therapy. Kidney Int Suppl 64 (1998) S61-S65
26. Richter W.O., Donner M.G., Selmaier A., Hiller E., and Schwandt P. Efficacy and safety of immunoglobulin apheresis. ASAIO J 43 1 (1997) 53-59
27. Schmaldienst S., Mullner M., Goldammer A., Spitzauer S., Banyai S., Horl W.H., et al. Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases?. Rheumatology (Oxford) 40 5 (2001) 513-521
28. Knobl P., Derfler K., Korninger L., Kapiotis S., Jager U., Maier-Dobersberger T., et al. Elimination of acquired factor VIII antibodies by extracorporal antibody-based immunoadsorption (Ig-Therasorb). Thromb Haemost 74 4 (1995) 1035-1038
29. Tribl B., Knobl P., Derfler K., Kapiotis S., Aspock G., Jager U., et al. Rapid elimination of a high-titer spontaneous factor V antibody by extra corporeal antibody-based immunoadsorption and immuno- suppression. Ann Hematol 71 4 (1995) 199-203
30. Smolen J.S., Strand V., Cardiel M., Edworthy S., Furst D., Gladman D., et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol 26 2 (1999) 504-507
31. Stummvoll G.H., Aringer M., Smolen J.S., Schmaldienst S., Jimenez-Boj E., Horl W.H., et al. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis 64 7 (2005) 1015-1021
32. Palmer A., Cairns T., Dische F., Gluck G., Gjorstrup P., Parsons V., et al. Treatment of rapidly progressive glomerulonephritis by extracorporeal immunoadsorption, prednisolone and cyclophosphamide. Nephrol Dial Transplant 6 8 (1991) 536-542
33. Schmaldienst S., Jansen M., Hollenstein U., Graninger W., Regele H., Horl W.H., et al. Treatment of systemic lupus erythematosus by immunoadsorption in a patient suffering from tuberculosis. Am J Kidney Dis 39 2 (2002) 415-418
34. Dittrich E., Schmaldienst S., Langer M., Jansen M., Horl W.H., and Derfler K. Immunoadsorption and plasma exchange in pregnancy. Kidney Blood Press Res 25 4 (2002) 232-239
35. Stummvoll G.H., Aringer M., Jansen M., Smolen J.S., Derfler K., and Graninger W.B. Immunoadsorption (IAS) as a rescue therapy in SLE: considerations on safety and efficacy. Wien Klin Wochenschr 116 21-22 (2004) 716-724
36. Rech J., Hueber A.J., Kallert S., Requadt C., Kalden J.R., and Schulze-Koops H. Immunoadsorption and CD20 antibody treatment in a patient with treatment resistant systemic lupus erythematosus and preterminal renal insufficiency. Ann Rheum Dis 65 4 (2006) 552-553
37. Terman D.S. Protein A and staphylococcal products in neoplastic disease. Crit Rev Oncol Hematol 4 2 (1985) 103-124
38. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40 9 (1997) 1725
39. Braun N., Erley C., Klein R., Kotter I., Saal J., and Risler T. Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus. Nephrol Dial Transplant 15 9 (2000) 1367-1372
40. Dantal J., Godfrin Y., Koll R., Perretto S., Naulet J., Bouhours J.F., et al. Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol 9 9 (1998) 1709-1715
41. Schmaldienst S., Jansen M., Hollenstein U., Graninger W., Regele H., Horl W.H., et al. Treatment of systemic lupus erythematosus by immunoadsorption in a patient suffering from tuberculosis. Am J Kidney Dis 39 2 (2002) 415-418
42. Jansen M., Schmaldienst S., Banyai S., Quehenberger P., Pabinger I., Derfler K., et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 112 1 (2001) 91-97
43. Smolen J.S. Clinical and serologic features: incidence and diagnostic approach. In: Smolen J.S., and Zielinski C.C. (Eds). Systemic lupus erythema tosus (1987), Springer Verlag, Berlin 171-196 Ref Type: Serial (Book, Monograph)
44. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., and Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35 6 (1992) 630-640
45. Petri M., Buyon J., and Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 8 8 (1999) 685-691
46. Mistry-Burchardi N., Schonermarck U., and Samtleben W. Apheresis in lupus nephritis. Ther Apher 5 3 (2001) 161-170
47. Wallace D.J. Apheresis for lupus erythematosus: state of the art. Lupus 10 3 (2001) 193-196